About Us
Targeting inflammation
Management Team
Board of Directors
Corporate Governance
Development
INV102 (nadolol)
INV103 (ala-Cpn10)
INV104 (zafirlukast)
Investors
Annual Reports
Financial Reports
Investor Presentations
Analyst Coverage
News & Media
Market Announcements
Investor and Media Contact
Clinical Trials
Chronic Bronchitis
Asthma
Systemic Lupus Erythematosus
Contact
ASX:IVX
Home
›
2013
›
October
Monthly Archives:
October 2013
October 31, 2013
Dr Mitchell Glass to speak at breakfast presentation: Drugs & diagnostics – navigating the FDA approval chain
October 31, 2013
Appendix 4C – quarterly cashflow statement
October 29, 2013
MD & CEO, Dr Greg Collier, discusses the in-licence of INV104 (zafirlukast)
October 28, 2013
Invion enters into global licence agreement for inhaled zafirlukast: INV104
October 28, 2013
Corporate presentation – October 2013
October 22, 2013
Notice of Annual General Meeting
October 15, 2013
Change to composition of Executive
October 1, 2013
Change of registered office and principal place of business
Latest Releases
Appendix 4E and Financial Report for year ended 30 June 2017
Invion announces strategic transaction
Appendix 4C – June 2017 Quarter
Appendix 4C – March 2017 Quarter
Invion announces strategic alliance
News & Media Archive
August 2017
July 2017
April 2017
February 2017
January 2017
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
News & Media
Analyst Coverage
Annual Review
ASX Releases
Financial Reports
Presentations
